Life Sciences success stories
Spin-out: Septerna Inc. was launched with US$100 million in financing to discover and advance novel small molecules medicines that target G-proten-coupled receptors (GPCRs).
Pio Therapeutics (Pio Tx)
Spin-out: A world-class team at Pio Tx is developing novel, innovative and targeted medicines that improve outcomes for cancer patients. Pio Tx focuses on medicines that increase endogenous anti-tumour immunity.
Monash University received $5 million from the Victorian Government to manufacture the first Australian batch of a COVID-19 mRNA vaccine for clinical trials.
Janssen – Coeliac collaboration
Monash and Janssen Biotech, Inc are working together to advance understanding of the immune mechanisms underpinning coeliac disease and inform the development of new methods of diagnosis and treatment.
With gram-negative ‘superbugs’ topping the World Health Organisation’s Priority Pathogen List for which new antibiotics are urgently needed, Monash researchers have developed novel polymyxin antibiotics to treat resistant pathogens.
Spin-out: RAGE Biotech is developing novel therapies designed to help patients with chronic inflammatory lung diseases such as severe asthma, cystic fibrosis and chronic obstructive pulmonary disease.
An innovative research partnership between Monash University and Melbourne-based start-up, oNKo-innate Pty Ltd is developing novel approaches to immunotherapy using expertise in natural killer (NK) cell biology.
Low FODMAP diet app
Spin-out: Launched in response to an increasing number of requests about the FODMAP content of foods, the Monash University Low FODMAP diet smartphone application helps users manage symptoms of IBS by restricting foods that are high in certain short-chain-carbohydrates.
AstraZeneca – Lupus collaboration
The AstraZeneca monoclonal antibody anifrolumab was shown in phase 3 clinical trials to achieve a statistically significant reduction in disease activity versus a placebo, offering real hope for a disease that affects 20,000 young Australian women.
Spin-out: AskPCOS is the first evidence-based polycystic ovary syndrome app. Through research and collaboration of leading global PCOS experts, the app is helping women to get a clear diagnosis and to access key information.
Spin-out: Monash researchers have collaborated on a technology to treat fibrosis – a condition associated with many chronic diseases, where tissue damage leads to scarring and loss of organ function.
Pfizer – Cancer research
Underpinned by research carried out at the Monash Institute of Pharmaceutical Sciences, Cancer Therapeutics CRC partnered with Pfizer for a research collaboration and licence deal that includes advanced molecules and could be a game-changer in the way cancer is treated in the future.
Cincera Therapeutics Pty Ltd
Spin-out: Drug discovery research at Monash has resulted in a spin-out company developing therapies for metabolic syndrome and type-2 diabetes-related diseases.
PureTech Health – Drug delivery
The Monash Institute of Pharmaceutical Sciences has licensed a lymphatic drug targeting technology platform to the clinical-stage biopharmaceutical company PureTech Health plc.
In a bid to prevent death during childbirth as a consequence of unchecked postpartum haemorrhage, Monash researchers have collaborated with healthcare workers and women in developing countries to design an oxytocin inhaler that can be used with minimal training, is stable at room temperature and resistant to degradation.
Medicines Manufacturing Innovation Centre (MMIC)
The Centre has a focus on growing exports of medicines manufactured in Victoria and supports pharmaceutical manufacturers and allied industries.
Johnson & Johnson Innovation
JJIPO@MONASH facilitates access by Victorian researchers and companies to the expertise across Johnson & Johnson’s scientist research, investor and commercial business arms.
Spin-out: Mogrify is developing novel technologies to direct cellular programming and to identify optimal culture conditions.
Starpharma – AstraZeneca
A long standing collaboration between Monash scientists and the Melbourne-based biotechnology company Starpharma reached a significant commercialisation milestone with Starpharma signing a major licencing deal with Astra Zeneca.
GlaxoSmithKline (GSK) – Drug formulation / delivery
By bringing together Monash University's world-leading drug delivery and formulation development expertise and GSK's industry and manufacturing capabilities, this collaboration translates cutting-edge science into next-generation pharmaceutical products.
Capsugel – Drug delivery
A novel drug delivery technology that uses lipid-like counter-ions to transform crystalline drugs into ionic liquids is expected to result in reduced absorption variability, decreased excipient levels and reduced pill burden.
Aravax – Peanut allergy
Spin-out: Monash researchers working in conjunction with Alfred Health have developed a specific peptide immunotherapy as a safe treatment for peanut allergy.
Takeda – Gastrointestinal diseases and disorders
Monash and Takeda scientists are working together to research the mechanisms that underlie some of the common and debilitating GI disorders that afflict millions of people worldwide.
Servier – Drug discovery
Monash is involved in a significant collaboration with Servier, a French pharmaceutical company, to develop new drugs against G-protein coupled receptors (GPCRs).
World Mosquito Program
With a uniquely self-sustaining method, the World Mosquito Program has the potential to transform the global fight against life-threatening viral diseases.
Spin-out: The Monash In Vitro Fertilisation research program resulted in the first human IVF pregnancy in 1973. Monash IVF have continued to achieve many Australian and world firsts, enabling new technologies to be delivered to patients as soon as they're available.
Relenza – Influenza Drug
After more than twenty years in the making, the influenza drug Relenza was approved for human use – a milestone for Australia’s scientific community. Relenza was launched as an orally inhaled drug, the first in a new generation of specific treatments for flu.
Acrux – Drug delivery
Spin-out: Acrux is a spin-off biotech company from Monash, recognised for its innovative technology in administering drugs through the skin.